Recruiting studies: Stage Iv Or Recurrent Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05681780 Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642 A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Sta
Phase 3 · 320 location(s) · Bristol-Myers Squibb · NCT06561386 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086 Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Phase 2 · 71 location(s) · Iovance Biotherapeutics, Inc. · NCT04614103 Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Phase 1/Phase 2 · 1 location(s) · Precision Biotech Taiwan Corp. · NCT04616209 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · 386 location(s) · SWOG Cancer Research Network · NCT06616584 An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Pat
Phase 4 · 39 location(s) · AstraZeneca · NCT07357597 PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT05234307 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A L
Phase 2 · 454 location(s) · SWOG Cancer Research Network · NCT05642572 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 603 location(s) · National Cancer Institute (NCI) · NCT04181060 First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07355205 Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-M
Phase 2 · 248 location(s) · SWOG Cancer Research Network · NCT06116682 Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung
Phase 2 · 266 location(s) · SWOG Cancer Research Network · NCT06031688 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210 Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623 SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · University of Washington · NCT05570825 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →